Bionas launches new Bionas adcon reader for impedance-based, cellular analysis

NewsGuard 100/100 Score
Bionas GmbH announces the launch of its new Bionas® adcon reader for impedance-based, cellular analysis. The Bionas adcon reader technology is based on real-time monitoring of cellular impedance, thus giving real-time data about cell adhesion, membrane integrity, cellular morphology and cell proliferation for applications in toxicology, oncology, receptor signaling as well as the quality management of cells.  Bionas technology allows for the analysis of cellular behavior in real-time without the use of any dyes or antibodies, thus avoiding the result being biased by the manipulation of the cells during the assay. The Bionas adcon reader consists of the Bionas plate station, the Bionas analyzer and a control unit (PC) and offers easy handling in 96-well format for laboratory research and HTS applications.

Also this summer, Bionas will launch the Bionas® 15002 RtU-Transporter system, an advancement of the existing two-channel Bionas 15002 analyzing system, but especially adapted for the analysis of membrane transport mechanisms and their role in multidrug resistances. It is the first automatic, label-free test system in the area of membrane transporter research, measuring impedance, O2-consumption and acidification. 

With the new analyzing systems, Bionas is responding to the increasing demand of the life science community for label-free, real-time assays.  Bionas is convinced that the recognized Bionas® 2500 analyzing system, for real-time monitoring of impedance (adhesion), acidification and O2-consumption, will be perfectly complemented by the new Bionas adcon reader and the Bionas 15002 RtU-Transporter system. The Bionas 2500 analyzing system so far, is the only analyzing system that generates real-time data of three parameters in parallel.

With this expansion of its product portfolio and the resulting applications, Bionas continuous to offer promising solutions and applications to its customers at the same time building on the advantage of label-free technology.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New microfluidic device improves the separation of tumor cells and clusters from malignant effusions